Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A. Jara Sánchez C, et al. Among authors: munarriz b. Breast Cancer Res Treat. 2007 Jan;101(2):215-23. doi: 10.1007/s10549-006-9282-0. Epub 2006 Jul 6. Breast Cancer Res Treat. 2007. PMID: 16823507
Time-to-progression in breast cancer: a stratification model for clinical trials.
de la Haba-Rodríguez J, Aranda E, Llombart A, Lluch A, Alba E, Munárriz B, Adrover E, Tusquets I, Balil A, Barnadas A, Calvo L, Martín M; Grupo Español de Investigación en Cáncer de Mama (GEICAM). de la Haba-Rodríguez J, et al. Among authors: munarriz b. Breast. 2008 Jun;17(3):239-44. doi: 10.1016/j.breast.2007.09.007. Epub 2007 Nov 26. Breast. 2008. PMID: 18042386
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. Among authors: munarriz b. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Martín M, et al. Among authors: munarriz b. N Engl J Med. 2010 Dec 2;363(23):2200-10. doi: 10.1056/NEJMoa0910320. N Engl J Med. 2010. PMID: 21121833 Free article. Clinical Trial.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Prat A, et al. Among authors: munarriz b. Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7. Br J Cancer. 2014. PMID: 25101563 Free PMC article.
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Martin M, et al. Among authors: munarriz b. Ann Oncol. 2003 Jun;14(6):833-42. doi: 10.1093/annonc/mdg260. Ann Oncol. 2003. PMID: 12796019 Free article. Review.
Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).
Colomer R, Viñas G, Beltran M, Izquierdo A, Lluch A, Llombart-Cussac A, Alba E, Munárriz B, Martín M; Spanish Breast Cancer Research Group. Colomer R, et al. Among authors: munarriz b. J Clin Oncol. 2004 Mar 1;22(5):961-2. doi: 10.1200/JCO.2004.99.143. J Clin Oncol. 2004. PMID: 14990656 No abstract available.
29 results